Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: a systematic literature review Expert Rev Hematol
Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group Blood Cancer J
Hypomethylating agents for patients with VEXAS without myelodysplastic syndrome: Clinical outcome and longitudinal follow-up of vacuolization and UBA1 clonal dynamics BRIT J HAEMATOL
Diagnosing Helicobacter pylori using autoencoders and limited annotations through anomalous staining patterns in IHC whole slide images INT J COMPUT ASS RAD
Endothelial Damage in JAK2V617F Myeloproliferative Neoplasms with Splanchnic Vein Thrombosis THROMB HAEMOSTASIS
Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial Eur J Haematol
The Human Microglia Atlas (HuMicA) unravels changes in disease-associated microglia subsets across neurodegenerative conditions Nat Commun
Lifetime Treatment Trajectories of Mantle Cell Lymphoma: Simulation Based Analysis of 20 Years of Real-World Data Hematol Oncol
Preclinical development of three novel CARs targeting CD79b for the treatment of non-Hodgkin's lymphoma and characterization of the loss of the target antigen J Immunother Cancer